Saturday, Sept. 26, 2020 : Issue #1066

TOP STORIES - Diabetes News & Research

The Risk of T2D in Children Using Selective Serotonin Reuptake Inhibitors

Diabetes and Subsequent Weight Loss Linked to an Increased Risk of Pancreatic Cancer

SGLT-2 Inhibitors and the Risk for Urosepsis

Letter from the Editor

For years a high body mass index or obesity has been associated with pancreatic cancer, and diabetes has also been seen as an indicator of a greater propensity for developing pancreatic cancer. With these two factors in mind, common logic would say that if your diabetes patient loses weight their risk of cancer will decrease as well.

When we were discussing this in a Zoom meeting last week, one of my interns brought me a different story. Destiny Funchess, PharmD Candidate, South College School of Pharmacy, found the results of a study looking at over 155,000 people, and what she found about diabetes, obesity, and weight loss will surprise you.

*****************************

We can make a difference!

*****************************

Dave Joffe

Editor-in-chief

Newsflash: Recall of Metformin Hydrochloride for Extended-Release Oral Suspension by Sun Pharmaceutical Industries

Sun Pharmaceutical Industries is recalling one lot (AB06381) of RIOMET ER (metformin hydrochloride for extended-release oral suspension), 500 mg per 5 mL due to the level of N-Nitrosodimethylamine (NDMA), which has been found to be above the allowable Acceptable Daily Intake limit established by the FDA. NDMA is classified as a probable human carcinogen (a substance that could cause cancer) based on results from laboratory tests.

Read recall

Coming October 6! A special report on how "Artificial Intelligence" (AI) optimizes care for T2D patients

In our October 6 issue, we will present "The Future of Type 2 Diabetes Management and The Changing Roles of Healthcare Professionals," the first in a three-part series. The series is about how a team of physicians and pharmacists at St. Elizabeth in Kentucky uses artificial intelligence to improve treatment, adherence, and cost savings for both Medicaid and Americans.

Did You Know? Fasting Blood Glucose Predicts Mortality In Patients with COVID-19 Independently of Diabetes History:

Current studies have shown that diabetes has been uniformly reported to be associated with poor prognosis in coronavirus infections. This study investigated the correlation between diabetes history and prognosis of COVID-19, and is the first study to focus on the direct correlation between fasting blood glucose (FBG) levels and the prognosis of COVID-19.

Outcomes of patients with and without pre-existing diabetes were compared. The associations of diabetes history and FBG levels with mortality were analyzed. Multivariate cox regression analysis on the risk factors associated with mortality in patients with COVID-19 was performed. There was a positive relationship between pre-existing diabetes and the mortality of patients who developed COVID-19. Moreover, FBG ≥126mg/L. (7.0 mmol/L) was an independent risk factor for the mortality of COVID-19 regardless of the presence or not of a history of diabetes.

The findings indicated screening FBG level is an effective method to evaluate the prognosis of patients with COVID-19. Intervention should be taken in patients with FBG ≥126mg/dL.(7.0 mmol/L) regardless of the presence or not of diabetes history.

Diabetes Research and Clinical Practice Sept. 10, 2020

Diabetes in Control gratefully acknowledges the assistance of the following pharmacy doctoral candidates in the preparation of this week’s newsletters:

Brianna Belton, PharmD. Candidate, Florida Agricultural & Mechanical University, College of Pharmacy and Pharmaceutical Sciences

Destiny Funchess, PharmD Candidate, Tougaloo College, South College School of Pharmacy

Joel John, Pharm.D. Candidate, Florida A&M University, College of Pharmacy & Pharmaceutical Sciences

Joan Prifti, PharmD. Candidate, LECOM College of Pharmacy

Destiny Reed, PharmD. Candidate, Florida A&M College of Pharmacy and Pharmaceutical Sciences

Jessica Rogers, PharmD Candidate, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences

About LaterPay: You will notice that some of our articles are now marked with a small credit card icon. This means you will be asked to pay a small fee to access the full article text (the cost is $0.39 per article, and you will be charged only after you have reached $5.00 in article views). The costs of producing a newsletter like Diabetes in Control have been increasing, which is why we are asking our readers to help support our ability to continue to bring you quality information about diabetes through charging a minimal price to read certain articles. Thank you for helping to support Diabetes in Control.

Your Friends in Diabetes Care
Steve and Dave
Diabetes In Control
810 Bear Tavern Road Suite 102
Ewing, NJ, 08628
USA
www.diabetesincontrol.com